PRISM: determination of the performance characteristics of ReQuest in practice in the stepped down management of GORD [gastro-oesophageal reflux disease]

Trial Profile

PRISM: determination of the performance characteristics of ReQuest in practice in the stepped down management of GORD [gastro-oesophageal reflux disease]

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Pantoprazole (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Therapeutic Use
  • Acronyms PRISM
  • Sponsors Fougera Pharmaceuticals
  • Most Recent Events

    • 04 May 2012 Additional company (Takeda Global Research and Development Center) added in association as reported by ClinicalTrials.gov.
    • 07 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top